BioLife Solutions, Inc.
BLFS
$21.90
$0.914.34%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 44.21% | 29.69% | -3.11% | -8.23% | -113.87% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 44.21% | 29.69% | -3.11% | -8.23% | -113.87% |
| Cost of Revenue | 22.38% | 23.30% | -26.23% | -17.32% | -150.16% |
| Gross Profit | -7.38% | 35.85% | 35.10% | 1.64% | -37.21% |
| SG&A Expenses | 2.17% | -5.07% | -17.13% | -12.61% | -69.40% |
| Depreciation & Amortization | 100.49% | -30.64% | -35.28% | -35.50% | -142.09% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.76% | -0.58% | -23.69% | -16.59% | -116.06% |
| Operating Income | -46.07% | 82.17% | 75.79% | 47.41% | 125.84% |
| Income Before Tax | -86.42% | 88.97% | -29.55% | 52.59% | 123.06% |
| Income Tax Expenses | 43.78% | -124.35% | -- | 31.52% | -174.12% |
| Earnings from Continuing Operations | -85.56% | 89.22% | -29.50% | 51.70% | 123.57% |
| Earnings from Discontinued Operations | 140.62% | -- | -189.96% | -20.35% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 183.30% | 94.15% | -103.15% | 25.47% | 69.59% |
| EBIT | -46.07% | 82.17% | 75.79% | 47.41% | 125.84% |
| EBITDA | -44.30% | 113.61% | 94.90% | 60.21% | 173.23% |
| EPS Basic | 180.04% | 94.48% | -91.82% | 29.40% | 70.97% |
| Normalized Basic EPS | -43.75% | 81.79% | 74.91% | 51.00% | 125.33% |
| EPS Diluted | 176.93% | 94.48% | -91.82% | 29.40% | 70.97% |
| Normalized Diluted EPS | -45.38% | 81.79% | 74.91% | 51.00% | 125.33% |
| Average Basic Shares Outstanding | 4.07% | 5.98% | 5.90% | 5.58% | 4.75% |
| Average Diluted Shares Outstanding | 7.16% | 5.98% | 5.90% | 5.58% | 4.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
